<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01700192</url>
  </required_header>
  <id_info>
    <org_study_id>P05607</org_study_id>
    <secondary_id>MK-8237-001</secondary_id>
    <nct_id>NCT01700192</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)</brief_title>
  <official_title>A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ALK-Abelló A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ALK-Abelló A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of MK-8237 (SCH 900237) in the
      treatment of House Dust Mite (HDM)-Induced Allergic Rhinitis/Rhinoconjunctivitis (AR/ARC) in
      children and adults.

      The primary hypothesis of this study is that administration of MK-8237, compared to placebo,
      results in significant reduction in the average total combined rhinitis score (TCRS).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Total Combined Rhinitis Score (TCRS) During Last 8 Weeks of Treatment</measure>
    <time_frame>Last 8 weeks of treatment (Weeks 44 to 52)</time_frame>
    <description>The TCRS is the sum of the rhinitis Daily Symptom Score (DSS; range: 0 to 12) and the rhinitis Daily Medication Score (DMS; range: 0 to 12); the total possible TCRS ranges from 0 to 24 points with higher scores indicative of greater symptom severity. The endpoint was calculated as the average daily diary entry score from the last 8 weeks of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Experience At Least One Adverse Event (AE)</measure>
    <time_frame>Up to 54 weeks</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinue Study Drug Due to an AE</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average Rhinitis Daily Symptom Score (Rhinitis DSS) During Last 8 Weeks of Treatment</measure>
    <time_frame>Last 8 weeks of treatment (Weeks 44 to 52)</time_frame>
    <description>The Rhinitis DSS ranges from a score of 0 to 12 (higher scores indicative of greater symptom severity). The endpoint was calculated as the average daily diary entry score from the last 8 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Rhinitis Daily Medication Score (Rhinitis DMS) During Last 8 Weeks of Treatment</measure>
    <time_frame>Last 8 weeks of treatment (Weeks 44 to 52)</time_frame>
    <description>The Rhinitis DMS ranges from a score of 0 to 12 (higher scores indicative of greater symptomatic medication use). The endpoint was calculated as the average daily diary entry score from the last 8 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Total Combined Rhinoconjunctivitis Score (TCS) During Last 8 Weeks of Treatment</measure>
    <time_frame>Last 8 weeks of treatment (Weeks 44 to 52)</time_frame>
    <description>The TCS is the sum of the rhinoconjunctivitis DSS (rhinitis DSS and conjunctivitis DSS; range: 0 to 18) and the rhinoconjunctivitis DMS (rhinitis DMS and conjunctivitis DMS; range: 0 to 20); the total possible TCS ranges from 0 to 38 points with higher scores indicative of greater symptom severity. The endpoint was calculated as the average daily diary entry score from the last 8 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Allergic Rhinitis/Rhinoconjunctivitis Symptoms Assessed by Visual Analogue Scale (VAS) During Last 8 Weeks of Treatment</measure>
    <time_frame>Last 8 weeks of treatment (Weeks 44 to 52)</time_frame>
    <description>Participants indicated the severity of symptoms in the past week on a VAS with a score range of 0 (&quot;no symptoms&quot;) to 100 (&quot;severe symptoms&quot;). Symptoms were assessed during 2 clinic visits occurring during the final 8 weeks of treatment (VAS score reflects the mean of 2 scores).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1482</enrollment>
  <condition>Rhinitis, Allergic, Perennial</condition>
  <condition>Rhinitis, Allergic, Nonseasonal</condition>
  <arm_group>
    <arm_group_label>MK-8237</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-8237 12 Development Units (DU) rapidly dissolving tablets administered sublingually once daily (q.d.).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MK-8237 tablets</intervention_name>
    <description>MK-8237 12 DU rapidly dissolving tablets administered sublingually q.d.</description>
    <arm_group_label>MK-8237</arm_group_label>
    <other_name>SCH 900237</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo tablets</intervention_name>
    <description>Placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rescue Medication: Self-Injectable Epinephrine</intervention_name>
    <description>Self-injectable epinephrine (preferred dose of 0.30 mg) administered intramuscularly as needed for rescue medication.</description>
    <arm_group_label>MK-8237</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rescue Medication: Loratadine tablets</intervention_name>
    <description>Loratadine tablet 10 mg administered orally as needed for rescue medication.</description>
    <arm_group_label>MK-8237</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rescue Medication: Olopatadine ophthalmic drops</intervention_name>
    <description>Olopatadine hydrochloride ophthalmic drops 0.1% administered as needed for rescue medication.</description>
    <arm_group_label>MK-8237</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rescue Medication: Mometasone furoate nasal spray</intervention_name>
    <description>Mometasone furoate monohydrate nasal spray 50 mcg administered intranasally as needed for rescue medication.</description>
    <arm_group_label>MK-8237</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of AR/ARC to house dust of 1 year duration or more (with or without asthma)

          -  If female of childbearing potential, has a negative urine pregnancy test at Screening
             and agrees to remain abstinent or use (or have their partner use) an acceptable method
             of birth control within the projected duration of the study

          -  Able to read, understand and complete questionnaires and diaries

        Exclusion Criteria:

          -  Clinically relevant history of symptomatic ARC caused by animal dander, molds and/or
             cockroach (e.g. present in the home, job, daycare, etc.) or other perennial allergen

          -  History of symptomatic seasonal ARC and/or asthma due to an allergen to which the
             participant is sensitized and regularly exposed

          -  Nasal condition that could confound the efficacy or safety assessments (e.g., nasal
             polyposis)

          -  Received an immunosuppressive treatment within 3 months prior to screening

          -  Unstable or severe asthma, or has experienced a life-threatening asthma attack or an
             occurrence of any clinical deterioration of asthma that resulted in emergency
             treatment, hospitalization due to asthma, or treatment with systemic corticosteroids
             (but allowing short-acting beta agonists [SABAs]) at any time within 3 months prior to
             screening

          -  Asthma requiring high-dose inhaled corticosteroids (ICS) within 6 months prior to
             screening

          -  History of anaphylaxis with cardiorespiratory symptoms with prior immunotherapy,
             unknown cause or inhalant allergen

          -  History of chronic urticaria and/or angioedema within 2 years prior to screening

          -  History of chronic sinusitis during 2 years prior to screening

          -  Pregnant, breastfeeding, or expecting to conceive within the projected duration of the
             study

          -  Previous immunotherapy treatment with any HDM allergen for more than 1 month within 5
             years prior to screening

          -  Previous exposure to MK-8237

          -  Receiving ongoing treatment with any specific immunotherapy at screening

          -  Known history of allergy, hypersensitivity or intolerance to investigational medicinal
             products (except for D. pteronyssinus and/or D. farinae), rescue medications or
             self-injectable epinephrine

          -  Unable to meet medication washout requirements prior to screening

          -  Unable or unwilling to comply with the use of self-injectable epinephrine

          -  Business or personal relationship with investigational site personnel or Sponsor who
             is directly involved with the conduct of the study

          -  Likely to travel for extended periods of time during the efficacy assessment period

          -  Participating in a different investigational study at any site during this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Nolte H, Bernstein DI, Nelson HS, Kleine-Tebbe J, Sussman GL, Seitzberg D, Rehm D, Kaur A, Li Z, Lu S. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2016 Dec;138(6):1631-1638. doi: 10.1016/j.jaci.2016.06.044. Epub 2016 Aug 10.</citation>
    <PMID>27521719</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2012</study_first_submitted>
  <study_first_submitted_qc>October 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2012</study_first_posted>
  <results_first_submitted>January 11, 2017</results_first_submitted>
  <results_first_submitted_qc>January 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 3, 2017</results_first_posted>
  <last_update_submitted>September 14, 2017</last_update_submitted>
  <last_update_submitted_qc>September 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
    <mesh_term>Loratadine</mesh_term>
    <mesh_term>Olopatadine Hydrochloride</mesh_term>
    <mesh_term>Mometasone Furoate</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MK-8237</title>
          <description>Participants took MK-8237 12 development unit (DU) rapidly dissolving tablets administered sublingually once daily (q.d.) for up to one year.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants took placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d. for up to one year.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="741"/>
                <participants group_id="P2" count="741"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="740"/>
                <participants group_id="P2" count="741"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>All Participants as Treated (APaT)</title>
              <participants_list>
                <participants group_id="P1" count="743">Three participants randomized to receive placebo were given MK-8237 12 DU.</participants>
                <participants group_id="P2" count="738">Three participants randomized to receive placebo were given MK-8237 12 DU.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="561"/>
                <participants group_id="P2" count="613"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="180"/>
                <participants group_id="P2" count="128"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with study drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Technical problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="64"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Never received study drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Characteristics refer to all randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>MK-8237</title>
          <description>Participants took MK-8237 12 DU rapidly dissolving tablets administered sublingually q.d. for up to one year.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants took placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d. for up to one year.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="741"/>
            <count group_id="B2" value="741"/>
            <count group_id="B3" value="1482"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.9" spread="13.82" lower_limit="12" upper_limit="77"/>
                    <measurement group_id="B2" value="35.2" spread="13.74" lower_limit="12" upper_limit="85"/>
                    <measurement group_id="B3" value="35.1" spread="13.77" lower_limit="12" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="445"/>
                    <measurement group_id="B2" value="430"/>
                    <measurement group_id="B3" value="875"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="296"/>
                    <measurement group_id="B2" value="311"/>
                    <measurement group_id="B3" value="607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Total Combined Rhinitis Score (TCRS) During Last 8 Weeks of Treatment</title>
        <description>The TCRS is the sum of the rhinitis Daily Symptom Score (DSS; range: 0 to 12) and the rhinitis Daily Medication Score (DMS; range: 0 to 12); the total possible TCRS ranges from 0 to 24 points with higher scores indicative of greater symptom severity. The endpoint was calculated as the average daily diary entry score from the last 8 weeks of treatment.</description>
        <time_frame>Last 8 weeks of treatment (Weeks 44 to 52)</time_frame>
        <population>The analysis population consists of all randomized participants who received at least 1 dose of study drug and had data available.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8237</title>
            <description>Participants took MK-8237 12 DU rapidly dissolving tablets administered sublingually q.d. for up to one year.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants took placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d. for up to one year.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Total Combined Rhinitis Score (TCRS) During Last 8 Weeks of Treatment</title>
          <description>The TCRS is the sum of the rhinitis Daily Symptom Score (DSS; range: 0 to 12) and the rhinitis Daily Medication Score (DMS; range: 0 to 12); the total possible TCRS ranges from 0 to 24 points with higher scores indicative of greater symptom severity. The endpoint was calculated as the average daily diary entry score from the last 8 weeks of treatment.</description>
          <population>The analysis population consists of all randomized participants who received at least 1 dose of study drug and had data available.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="566"/>
                <count group_id="O2" value="620"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.67" spread="3.55"/>
                    <measurement group_id="O2" value="5.49" spread="3.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.20</ci_lower_limit>
            <ci_upper_limit>-0.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Treatment Difference Relative to Placebo</param_type>
            <param_value>-17.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.0</ci_lower_limit>
            <ci_upper_limit>-9.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experience At Least One Adverse Event (AE)</title>
        <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
        <time_frame>Up to 54 weeks</time_frame>
        <population>The All Participants as Treated (APaT) population consists of all randomized participants who received at least 1 dose of study drug (data presented according to actual treatment received).</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8237</title>
            <description>Participants took MK-8237 12 DU rapidly dissolving tablets administered sublingually q.d. for up to one year.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants took placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d. for up to one year.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experience At Least One Adverse Event (AE)</title>
          <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
          <population>The All Participants as Treated (APaT) population consists of all randomized participants who received at least 1 dose of study drug (data presented according to actual treatment received).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="743"/>
                <count group_id="O2" value="738"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="676"/>
                    <measurement group_id="O2" value="539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Discontinue Study Drug Due to an AE</title>
        <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
        <time_frame>Up to 52 weeks</time_frame>
        <population>The APaT population consists of all randomized participants who received at least 1 dose of study drug (data presented according to actual treatment received).</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8237</title>
            <description>Participants took MK-8237 12 DU rapidly dissolving tablets administered sublingually q.d. for up to one year.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants took placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d. for up to one year.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinue Study Drug Due to an AE</title>
          <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.</description>
          <population>The APaT population consists of all randomized participants who received at least 1 dose of study drug (data presented according to actual treatment received).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="743"/>
                <count group_id="O2" value="738"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Rhinitis Daily Symptom Score (Rhinitis DSS) During Last 8 Weeks of Treatment</title>
        <description>The Rhinitis DSS ranges from a score of 0 to 12 (higher scores indicative of greater symptom severity). The endpoint was calculated as the average daily diary entry score from the last 8 weeks of treatment.</description>
        <time_frame>Last 8 weeks of treatment (Weeks 44 to 52)</time_frame>
        <population>The analysis population consists of all randomized participants who received at least 1 dose of study drug and had data available.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8237</title>
            <description>Participants took MK-8237 12 DU rapidly dissolving tablets administered sublingually q.d. for up to one year.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants took placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d. for up to one year.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Rhinitis Daily Symptom Score (Rhinitis DSS) During Last 8 Weeks of Treatment</title>
          <description>The Rhinitis DSS ranges from a score of 0 to 12 (higher scores indicative of greater symptom severity). The endpoint was calculated as the average daily diary entry score from the last 8 weeks of treatment.</description>
          <population>The analysis population consists of all randomized participants who received at least 1 dose of study drug and had data available.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="566"/>
                <count group_id="O2" value="620"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.83" spread="2.64"/>
                    <measurement group_id="O2" value="4.46" spread="2.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.00</ci_lower_limit>
            <ci_upper_limit>-0.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Treatment Difference Relative to Placebo</param_type>
            <param_value>-15.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.4</ci_lower_limit>
            <ci_upper_limit>-7.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Rhinitis Daily Medication Score (Rhinitis DMS) During Last 8 Weeks of Treatment</title>
        <description>The Rhinitis DMS ranges from a score of 0 to 12 (higher scores indicative of greater symptomatic medication use). The endpoint was calculated as the average daily diary entry score from the last 8 weeks of treatment.</description>
        <time_frame>Last 8 weeks of treatment (Weeks 44 to 52)</time_frame>
        <population>The analysis population consists of all randomized participants who received at least 1 dose of study drug and had data available.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8237</title>
            <description>Participants took MK-8237 12 DU rapidly dissolving tablets administered sublingually q.d. for up to one year.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants took placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d. for up to one year.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Rhinitis Daily Medication Score (Rhinitis DMS) During Last 8 Weeks of Treatment</title>
          <description>The Rhinitis DMS ranges from a score of 0 to 12 (higher scores indicative of greater symptomatic medication use). The endpoint was calculated as the average daily diary entry score from the last 8 weeks of treatment.</description>
          <population>The analysis population consists of all randomized participants who received at least 1 dose of study drug and had data available.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="566"/>
                <count group_id="O2" value="620"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" spread="1.817"/>
                    <measurement group_id="O2" value="1.03" spread="2.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.154</p_value>
            <method>Zero-inflated Log-normal Model</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.35</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Treatment Difference Relative to Placebo</param_type>
            <param_value>-18.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-41</ci_lower_limit>
            <ci_upper_limit>4.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Total Combined Rhinoconjunctivitis Score (TCS) During Last 8 Weeks of Treatment</title>
        <description>The TCS is the sum of the rhinoconjunctivitis DSS (rhinitis DSS and conjunctivitis DSS; range: 0 to 18) and the rhinoconjunctivitis DMS (rhinitis DMS and conjunctivitis DMS; range: 0 to 20); the total possible TCS ranges from 0 to 38 points with higher scores indicative of greater symptom severity. The endpoint was calculated as the average daily diary entry score from the last 8 weeks of treatment.</description>
        <time_frame>Last 8 weeks of treatment (Weeks 44 to 52)</time_frame>
        <population>The analysis population consists of all randomized participants who received at least 1 dose of study drug and had data available.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8237</title>
            <description>Participants took MK-8237 12 DU rapidly dissolving tablets administered sublingually q.d. for up to one year.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants took placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d. for up to one year.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Total Combined Rhinoconjunctivitis Score (TCS) During Last 8 Weeks of Treatment</title>
          <description>The TCS is the sum of the rhinoconjunctivitis DSS (rhinitis DSS and conjunctivitis DSS; range: 0 to 18) and the rhinoconjunctivitis DMS (rhinitis DMS and conjunctivitis DMS; range: 0 to 20); the total possible TCS ranges from 0 to 38 points with higher scores indicative of greater symptom severity. The endpoint was calculated as the average daily diary entry score from the last 8 weeks of treatment.</description>
          <population>The analysis population consists of all randomized participants who received at least 1 dose of study drug and had data available.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="566"/>
                <count group_id="O2" value="620"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.40" spread="5.16"/>
                    <measurement group_id="O2" value="7.62" spread="5.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.70</ci_lower_limit>
            <ci_upper_limit>-0.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Treatment Difference Relative to Placebo</param_type>
            <param_value>-16.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.6</ci_lower_limit>
            <ci_upper_limit>-4.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Allergic Rhinitis/Rhinoconjunctivitis Symptoms Assessed by Visual Analogue Scale (VAS) During Last 8 Weeks of Treatment</title>
        <description>Participants indicated the severity of symptoms in the past week on a VAS with a score range of 0 (&quot;no symptoms&quot;) to 100 (&quot;severe symptoms&quot;). Symptoms were assessed during 2 clinic visits occurring during the final 8 weeks of treatment (VAS score reflects the mean of 2 scores).</description>
        <time_frame>Last 8 weeks of treatment (Weeks 44 to 52)</time_frame>
        <population>The analysis population consists of all randomized participants who received at least 1 dose of study drug and had data available.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-8237</title>
            <description>Participants took MK-8237 12 DU rapidly dissolving tablets administered sublingually q.d. for up to one year.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants took placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d. for up to one year.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Allergic Rhinitis/Rhinoconjunctivitis Symptoms Assessed by Visual Analogue Scale (VAS) During Last 8 Weeks of Treatment</title>
          <description>Participants indicated the severity of symptoms in the past week on a VAS with a score range of 0 (&quot;no symptoms&quot;) to 100 (&quot;severe symptoms&quot;). Symptoms were assessed during 2 clinic visits occurring during the final 8 weeks of treatment (VAS score reflects the mean of 2 scores).</description>
          <population>The analysis population consists of all randomized participants who received at least 1 dose of study drug and had data available.</population>
          <units>Score on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="540"/>
                <count group_id="O2" value="585"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.29" spread="23.57"/>
                    <measurement group_id="O2" value="47.96" spread="23.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-6.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.10</ci_lower_limit>
            <ci_upper_limit>-3.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Treatment Difference Relative to Placebo</param_type>
            <param_value>-16.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.7</ci_lower_limit>
            <ci_upper_limit>-8.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 54 weeks</time_frame>
      <desc>The APaT population consists of all randomized participants who received at least 1 dose of study drug (data presented according to actual treatment received).</desc>
      <group_list>
        <group group_id="E1">
          <title>MK-8237 12 DU</title>
          <description>Participants took MK-8237 12 DU rapidly dissolving tablets administered sublingually q.d. for up to one year.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants took placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d. for up to one year.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="743"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="738"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="743"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="738"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tympanic membrane perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="743"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="738"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oral pain</sub_title>
                <description>Due to overdose; classified as SAE by sponsor but does not meet International Council for Harmonisation (ICH) SAE criteria.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="743"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="738"/>
              </event>
              <event>
                <sub_title>Oral pruritus</sub_title>
                <description>Due to overdose; classified as SAE by sponsor but does not meet ICH SAE criteria.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="743"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="738"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="743"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="738"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="743"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="738"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="743"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="738"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="743"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="738"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="743"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="738"/>
              </event>
              <event>
                <sub_title>Infected bites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="743"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="738"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="743"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="738"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="743"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="738"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="743"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="738"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="743"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="738"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="743"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="738"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar I disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="743"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="738"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="743"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="738"/>
              </event>
              <event>
                <sub_title vocab="MedDRA v. 18.0">Alcohol abuse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="743"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="738"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="743"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="738"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Throat irritation</sub_title>
                <description>Due to overdose; classified as SAE by sponsor but does not meet ICH SAE criteria.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="743"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="738"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="743"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="738"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="743"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="738"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="642" subjects_at_risk="743"/>
                <counts group_id="E2" subjects_affected="389" subjects_at_risk="738"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pruritus</sub_title>
                <counts group_id="E1" events="1637" subjects_affected="382" subjects_at_risk="743"/>
                <counts group_id="E2" events="244" subjects_affected="92" subjects_at_risk="738"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="212" subjects_affected="92" subjects_at_risk="743"/>
                <counts group_id="E2" events="87" subjects_affected="44" subjects_at_risk="738"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="85" subjects_affected="55" subjects_at_risk="743"/>
                <counts group_id="E2" events="42" subjects_affected="27" subjects_at_risk="738"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" events="296" subjects_affected="119" subjects_at_risk="743"/>
                <counts group_id="E2" events="58" subjects_affected="26" subjects_at_risk="738"/>
              </event>
              <event>
                <sub_title>Lip swelling</sub_title>
                <counts group_id="E1" events="353" subjects_affected="140" subjects_at_risk="743"/>
                <counts group_id="E2" events="42" subjects_affected="19" subjects_at_risk="738"/>
              </event>
              <event>
                <sub_title>Mouth swelling</sub_title>
                <counts group_id="E1" events="165" subjects_affected="73" subjects_at_risk="743"/>
                <counts group_id="E2" events="32" subjects_affected="12" subjects_at_risk="738"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="196" subjects_affected="85" subjects_at_risk="743"/>
                <counts group_id="E2" events="41" subjects_affected="27" subjects_at_risk="738"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="293" subjects_affected="121" subjects_at_risk="743"/>
                <counts group_id="E2" events="111" subjects_affected="57" subjects_at_risk="738"/>
              </event>
              <event>
                <sub_title>Oral pruritus</sub_title>
                <counts group_id="E1" events="1966" subjects_affected="468" subjects_at_risk="743"/>
                <counts group_id="E2" events="277" subjects_affected="109" subjects_at_risk="738"/>
              </event>
              <event>
                <sub_title>Palatal swelling</sub_title>
                <counts group_id="E1" events="183" subjects_affected="82" subjects_at_risk="743"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="738"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" events="173" subjects_affected="71" subjects_at_risk="743"/>
                <counts group_id="E2" events="28" subjects_affected="21" subjects_at_risk="738"/>
              </event>
              <event>
                <sub_title>Swollen tongue</sub_title>
                <counts group_id="E1" events="255" subjects_affected="123" subjects_at_risk="743"/>
                <counts group_id="E2" events="31" subjects_affected="17" subjects_at_risk="738"/>
              </event>
              <event>
                <sub_title>Tongue ulceration</sub_title>
                <counts group_id="E1" events="232" subjects_affected="96" subjects_at_risk="743"/>
                <counts group_id="E2" events="29" subjects_affected="21" subjects_at_risk="738"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="81" subjects_affected="62" subjects_at_risk="743"/>
                <counts group_id="E2" events="68" subjects_affected="61" subjects_at_risk="738"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="76" subjects_affected="63" subjects_at_risk="743"/>
                <counts group_id="E2" events="87" subjects_affected="74" subjects_at_risk="738"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="143" subjects_affected="73" subjects_at_risk="743"/>
                <counts group_id="E2" events="48" subjects_affected="29" subjects_at_risk="738"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="43" subjects_affected="35" subjects_at_risk="743"/>
                <counts group_id="E2" events="63" subjects_affected="47" subjects_at_risk="738"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngeal oedema</sub_title>
                <counts group_id="E1" events="268" subjects_affected="109" subjects_at_risk="743"/>
                <counts group_id="E2" events="40" subjects_affected="23" subjects_at_risk="738"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="2144" subjects_affected="506" subjects_at_risk="743"/>
                <counts group_id="E2" events="505" subjects_affected="172" subjects_at_risk="738"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Corporate Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

